Searched for
IMMUNOADOPTIVE CELL THERAPY
Gene therapy for blood cancer shows 73 per cent response rate in clinical trialsResearchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-inco...- Sensex falls for second day, ends 194 pts lower, dragged by bank & fin stocksIndian equity indices closed lower for the second consecutive day due to investors booking profits. Bharti Airtel, Kotak Mahindra Bank, and...
- Laurus Labs shares rise over 4% as co acquires additional stake in lmmunoACTLaurus Labs is set to increase its stake in Immunoadoptive Cell Therapy (lmmunoACT) by 7.24% for $10.6m, taking its total stake in the comp...
- Laurus Labs invests Rs 80 crore in cell & gene therapy firm ImmunoACTThe fresh infusion of capital will enable ImmunoACT to fast-track the scale-up of its lead candidate HCAR-19 by expansion of the multi-loca...
- How Laurus Labs capex drive can impact its margins & valuationsRise in headwinds in the pharma industry due to inflation, increase in raw material costs, and excessive competition led to price erosion i...
- The week that was: Latent View logs 250% return in a week, Paytm makes a recoveryThe volatility was high with India VIX surging to 20.80 level from 14.85 level a week ago amid the expiry of the monthly F&O series. That s...
- Stocks in the news: Paytm, Reliance Industries, Bharti Airtel, Sun Pharma and Laurus LabsZydus Cadila said it has received approval from the US health regulator to market Decitabine injection, used to treat certain types of canc...
- Laurus Labs to buy 26% in CAR T-cell therapy companyFounded in 2018 by Dr Rahul Purwar and a team of scientists, ImmunoACT is collaborating with institutions like Tata Memorial Hospital. Carl...
- Laurus Labs acquires stake in IIT-Bombay incubated CAR-T cell therapy companyAs per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...
Load More
